CEACAM5 and medullary thyroid gland carcinoma: In conclusion, due to limited sensitivity and specificity CA 19.9 cannot replace established MTC biomarkers (i.e., calcitonin and CEA) but may serve as a useful adjunct in select CA 19.9-positive cases.